Inhibitors of Herpes Simplex Virus Thymidine Kinase Synthesis and Biological Properties

J A Martin, I B Duncan, M J Hall, R W Lambert, G J Thomas and P W Kai In Research Division, Roche Products Limited, P O Box 8, Welwyn Garden City, Hertfordshire AL7 3AY, England

Herpes simplex virus (HSV) encoded thymidine kinase (TK) has been implicated in the establishment and development of HSV infections in vivo. TK<sup>-</sup> mutants of this virus are known to have a modified propensity for spread within the nervous system and it follows that inhibition of this enzyme may influence the course of infection, especially aspects of latency. Inhibitors of HSV-TK might be expected to display antiviral activity in appropriate models but potent and selective inhibitors of this enzyme have not been described hitherto. We have designed and synthesised a range of novel nucleoside derivatives as product analogues that are potent (IC50  $10^{-9}$ M) and highly selective inhibitors of HSV-TK. The synthesis, structure-activity relationships and some biological properties of these compounds will be discussed.

Inhibition of HIV-1 and Simian Immunodeficiency Virus (SIV) Reverse Transcriptases by the 5'-Triphosphates of 3'-Azido-2',3'-dideoxyuridine (CS-87), 3'-Azido-3'-deoxythymidine (AZT), and 3'-Azido-2',3'-dideoxy-5-ethyluridine (CS-85). B. F. H. Eriksson<sup>1</sup>\*, R. F. Schinazi<sup>1</sup>, and C. K. Chu<sup>2</sup>. Veterans Administration Med. Ctr., and Emory University School of Medicine, Dept. of Pediatrics, Atlanta, Ga.<sup>1</sup>, and University of Georgia, Athens, Ga<sup>2</sup>.

Several 2',3'-dideoxynucleosides have been shown to be potent and preferential inhibitors of human immunodeficiency virus (HIV-1) replication *in vitro*. The major target enzyme affected is thought to be the HIV-1 reverse transcriptase (RT). RTs from HIV-1 (LAV)- and SIV (SMM)-infected cultures of human peripheral blood mononuclear cells were partially purified, and the effects of the 5'-triphosphates of CS-87, AZT, and CS-85 were investigated. All three triphosphates inhibited HIV-1 and SIV RTs in a competitive manner with respect to the normal substrate dTTP. The triphosphates of AZT and CS-87 were about equally potent against HIV-1 and SIV RTs, whereas CS-85-TP was about 10 times less potent. The apparent  $K_i$ -values of AZT-TP, CS-87-TP, and CS-85-TP using HIV-1 RT were 4.0, 5.9, and 50 nM, respectively, in  $(rA)_n \cdot (dT)_{12-18}$  directed reactions using 1  $\mu$ M dTTP. Corresponding  $K_i$ -values using SIV RT in similar reactions were 5.0, 7.5, and 45 nM, respectively. The  $K_m$  for dTTP was determined to be about 0.5  $\mu$ M and 1.5  $\mu$ M for HIV-1 and SIV RTs, respectively, showing that the triphosphates had a 30-300 times higher affinity for the enzymes than dTTP. Cellular DNA polymerase  $\alpha$  activity was reduced by 50% at 20-30  $\mu$ M AZT-TP or CS-87-TP and at 375  $\mu$ M CS-85-TP in reactions directed by activated calf thymus DNA, when dTTP was maintained at 1  $\mu$ M. These results indicate that AZT-TP and CS-87-TP are equally effective and selective inhibitors of HIV-1 and SIV RTs. Although CS-85-TP was about 10 times less potent, its selectivity was similar to the other antiviral nucleotides. (Supported by USPHS grant 44094, and the Veterans Administration)